The U.S. National Institute on Drug Abuse (NIDA) awarded a $9,145,390 Cooperative Agreement under the Drug Use and Addiction Research Programs (CFDA 93.279) to Ensysce Biosciences, Inc. in La Jolla, CA. The goal of this project is to continue the clinical development of PF614-MPAR, an abuse-resistant and overdose-protected opioid product. PF614-MPAR combines the TAAP (Trypsin Activated Abuse Protection) oxycodone prodrug with the trypsin inhibitor nafamostat to provide pain relief at...
This Project Grant award from the National Institute on Drug Abuse, under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $399,536 to Chemregen Inc. to design, synthesize, and test non-opioid drug candidates that could reverse the effects of synthetic opioids like fentanyl. The two-year project aims to characterize the effects of opioids on human induced pluripotent stem cell-derived neurons, with the goal of validating a molecular target and identifying lead compounds...
This $479,731 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support the development of NARCOBOND A2/MO, a "nanosponge" containing decoy receptors for the opioid fentanyl and the veterinary sedative xylazine. The goal is to create a treatment that can safely sequester both substances in the peripheral blood, preventing their entry into the central nervous system and reversing life-threatening...
This $4,920,000 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund a randomized controlled trial at the University of California, San Francisco (UCSF) to investigate the feasibility, acceptability, and preliminary effectiveness of using long-acting injectable naltrexone as a preventive measure for opioid overdose in individuals using stimulants and living with or at risk of HIV. The project aims to...
The National Institute on Drug Abuse (NIDA) has awarded a Cooperative Agreement grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Sparian Biosciences Inc., doing business as Palion Therapeutics, to develop SBS-226, a novel chemical entity utilizing mixed mu-opioid receptor (MOR) agonism and delta-opioid receptor (DOR) antagonism, for the treatment of opioid use disorder (OUD). The total funding amount is $11,872,077 over the period of Sep 30, 2024 to Aug 31,...
This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $9,570,002.00 to Nirsum Laboratories, Inc. to accelerate the advancement of NRS-033, a potential new medication for opioid use disorder (OUD), towards pivotal studies and FDA registration.
The key products and services to be delivered include: late-stage chemistry, manufacturing, and controls (CMC) for the active pharmaceutical...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $360,720 to conduct a randomized controlled trial examining the use of extended-release injectable buprenorphine compared to sublingual buprenorphine/naloxone for the treatment of opioid use disorder in individuals who use high-potency synthetic opioids. The primary objectives are to compare abstinence and relapse rates between the two...
This federal Project Grant award from the National Institutes of Health's National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) totaling $1,539,426 provides funding to Serodopa Therapeutics Inc. to develop a novel intranasal formulation of a naloxone derivative as an overdose reversal agent for opioid-induced respiratory depression caused by high-potency opioids like fentanyl. The goals of this Direct-to-Phase II SBIR project are to complete formulation...
The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $404,917 Project Grant to Quench Medical Inc. to develop and test an inhaled dry powder formulation containing the psychoplastogenic compound 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for treating opioid use disorder (OUD). The project aims to create a targeted inhalation treatment that can effectively and consistently deliver 5-MeO-DMT to the lungs and systemic...
The National Institute on Drug Abuse (NIDA) awarded a $144,362 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Trustees of Dartmouth College for the "Evaluation of a Pharmacist-Integrated Model of Opioid Use Disorder Treatment to Increase Naloxone Co-Prescribing in Primary Care" research project. This two-year grant aims to investigate whether integrating pharmacists into primary care can help increase the co-prescription of the opioid overdose...